OA19940A - Encapsulated Liver Cell Composition - Google Patents
Encapsulated Liver Cell Composition Download PDFInfo
- Publication number
- OA19940A OA19940A OA1201100385 OA19940A OA 19940 A OA19940 A OA 19940A OA 1201100385 OA1201100385 OA 1201100385 OA 19940 A OA19940 A OA 19940A
- Authority
- OA
- OAPI
- Prior art keywords
- liver
- cells
- liver cells
- erythropoietin
- microcapsules
- Prior art date
Links
- 210000004185 Liver Anatomy 0.000 title claims abstract description 149
- 239000000203 mixture Substances 0.000 title description 2
- 239000003094 microcapsule Substances 0.000 claims abstract description 69
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 67
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 67
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 64
- 239000002775 capsule Substances 0.000 claims abstract description 23
- 239000000725 suspension Substances 0.000 claims abstract description 21
- 230000004936 stimulating Effects 0.000 claims abstract description 17
- 210000004027 cells Anatomy 0.000 claims description 145
- 239000011257 shell material Substances 0.000 claims description 21
- 239000011159 matrix material Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 229940072056 alginate Drugs 0.000 claims description 7
- 235000010443 alginic acid Nutrition 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 239000001963 growth media Substances 0.000 claims description 7
- 201000009673 liver disease Diseases 0.000 claims description 7
- 230000001154 acute Effects 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 230000001684 chronic Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 230000002440 hepatic Effects 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 206010019663 Hepatic failure Diseases 0.000 claims description 3
- 210000003494 Hepatocytes Anatomy 0.000 claims description 3
- 208000007903 Liver Failure Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 210000003999 epithelial cell of bile duct Anatomy 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 231100000835 liver failure Toxicity 0.000 claims description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 2
- 201000011374 Alagille syndrome Diseases 0.000 claims description 2
- 241000287523 Ara Species 0.000 claims description 2
- 210000001367 Arteries Anatomy 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 206010004659 Biliary cirrhosis Diseases 0.000 claims description 2
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 206010017604 Galactosaemia Diseases 0.000 claims description 2
- 208000009139 Gilbert Disease Diseases 0.000 claims description 2
- 206010018267 Gilbert's syndrome Diseases 0.000 claims description 2
- 208000007345 Glycogen Storage Disease Diseases 0.000 claims description 2
- 206010018872 Haemochromatosis Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 208000006454 Hepatitis Diseases 0.000 claims description 2
- 208000005252 Hepatitis A Diseases 0.000 claims description 2
- 208000002672 Hepatitis B Diseases 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 206010057212 Hepatitis viral infection Diseases 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 208000001019 Inborn Errors Metabolism Diseases 0.000 claims description 2
- 206010062018 Inborn error of metabolism Diseases 0.000 claims description 2
- 108010047319 Jagged-1 Protein Proteins 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 201000007981 Reye syndrome Diseases 0.000 claims description 2
- 210000000952 Spleen Anatomy 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 210000003462 Veins Anatomy 0.000 claims description 2
- 201000001203 Wilson disease Diseases 0.000 claims description 2
- 231100000836 acute liver failure Toxicity 0.000 claims description 2
- 230000001058 adult Effects 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 201000005271 biliary atresia Diseases 0.000 claims description 2
- 231100000045 chemical toxicity Toxicity 0.000 claims description 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 201000002450 inherited metabolic disease Diseases 0.000 claims description 2
- 201000004044 liver cirrhosis Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000069 prophylaxis Effects 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 201000011296 tyrosinemia Diseases 0.000 claims description 2
- 208000003167 Cholangitis Diseases 0.000 claims 1
- 208000001130 Gallstone Diseases 0.000 claims 1
- 102000006832 Jagged-1 Protein Human genes 0.000 claims 1
- 239000000560 biocompatible material Substances 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 101700084039 EPO Proteins 0.000 description 27
- 102100002607 TIMP1 Human genes 0.000 description 27
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 11
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 10
- 239000011324 bead Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 230000003899 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006143 cell culture media Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 102100014691 CXCL12 Human genes 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229940053128 Nerve Growth Factor Drugs 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 229940005550 Sodium alginate Drugs 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005421 electrostatic potential Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100017923 ACOT12 Human genes 0.000 description 1
- 101710008266 ACOT12 Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229940115115 Aranesp Drugs 0.000 description 1
- 239000010754 BS 2869 Class F Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- SXVBHNXTPNLOKR-FCLWLKJISA-L Calcium alginate Chemical compound [Ca+2].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O SXVBHNXTPNLOKR-FCLWLKJISA-L 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 102100016635 EPOR Human genes 0.000 description 1
- 229950002109 Epoetin delta Drugs 0.000 description 1
- 229940089118 Epogen Drugs 0.000 description 1
- 210000004494 Erythroblasts Anatomy 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 210000004408 Hybridomas Anatomy 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100006542 JAG1 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 229940029238 Mircera Drugs 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- YLMGFJXSLBMXHK-UHFFFAOYSA-M Potassium perchlorate Chemical compound [K+].[O-]Cl(=O)(=O)=O YLMGFJXSLBMXHK-UHFFFAOYSA-M 0.000 description 1
- 229940029359 Procrit Drugs 0.000 description 1
- 102000036642 SCF complex Human genes 0.000 description 1
- 108091006943 SCF complex Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000036902 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000002737 ampicillanyl group Chemical group N[C@@H](C(=O)N[C@H]1[C@@H]2N([C@H](C(S2)(C)C)C(=O)*)C1=O)C1=CC=CC=C1 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010067416 epoetin delta Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010046015 ferritin receptor Proteins 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000018146 globin family Human genes 0.000 description 1
- 108060003196 globin family Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 101700051975 pbs-5 Proteins 0.000 description 1
- -1 phosphatidyl inositol glycan Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011099 tissue engineering Methods 0.000 description 1
- 230000001228 trophic Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Abstract
Microcapsules comprising a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact to a liver cell stimulating amount of erythropoietin.
Description
Encapsulated liver cell composition
The présent invention relates to microcapsules comprising liver cells and erythropoietin, methods to préparé said microcapsules and methods to treat a patient comprising applying said microcapsules to 5 the patient.
Although the liver of a healthy subject is able to regenerate itself by repairing or replacing injured or ill tissue, unfortunately once a certain amount of liver cells has died or has severely been damaged through disease or injuries, the whole organ may fail. Such a failure, be it an 10 acute or chronic failure, may cause disease and death. The therapy of liver diseases encompasses conventional means, such as the administration of drugs. However, it is also state of the art to transplant livers or parts thereof. Furthermore, it is widely known to transplant liver cell populations in patients, such as described for instance 15 in WO 2004/009766 A2. It is, however, still a major challenge in devising thérapies for curing acute or chronic hepatic diseases to deliver liver cells to a patient in need thereof which methods are optimized in terms of viability, engraftment, prolifération and différentiation of the transplanted liver cells in the target tissue.
Haque et al. (Biotechnology Letters 27 (5) (2005), 317 - 322)) describe in vitro studies of alginate-chitosan microcapsules as an alternative to liver cell transplants for the treatment of liver failure. Chandrasekaran et al. (Tissue Engineering 12 (7), (2006)) disclose hepatic progenitor cells embedded in electrostatically produced 25 beads.
202517g SC-bi-lb
April 2010
In spite of the efforts to develop therapeutic Systems which efficiently deliver liver cells into the patient’s target tissue, there still remains the need to provide more reliable therapeutic means to cure liver diseases, in particular means which provide a high viability and 5 physiological activity of the liver cells in the target body.
The présent teaching solves said problem by providing microcapsules comprising a capsule shell, preferably a biocompatible capsule shell, encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact to a liver cell stimulating 10 amount of erythropoietin. In a preferred embodiment the présent invention provides microcapsules comprising a capsule shell and a core, wherein the capsule shell encapsulâtes in the core a suspension of a therapeutically effective amount of liver cells and a liver cell stimulating amount of erythropoietin, in particular wherein the 15 erythropoietin (in the following termed EPO) and the liver cells are in physical contact to each other so as to provide a stimulating effect of the EPO to the liver cells.
Thus, in a preferred embodiment the présent invention foresees to provide microcapsules comprising a capsule shell, preferably made 20 from a biocompatible capsule shell material, and a core being enveloped by said capsule shell. In one preferred embodiment of the présent invention the core contains a suspension of a therapeutically effective amount of liver cells in physical contact to a liver cell stimulating amount of erythropoietin.
In another preferred embodiment the core contains a matrix, preferably made from a biocompatible matrix material, wherein the suspension of the therapeutically effective amount of liver cells is em bedded in said matrix in physical contact to a liver cell stimulating amount of erythropoietin. Preferably, the material of the matrix is the same as the capsule shell material. In another embodiment the biocompatible matrix material may be another material than the capsule shell material.
Thus, the présent invention provides the teaching to encapsulate both erythropoietin and liver cells together in a biocompatible capsule shell such that the erythropoietin is in physical contact to the liver cells so as to exert at least one of its biological functions on the liver cells, in particular in stimulating the liver cells.
One advantage of the présent invention is that the liver cells are encapsulated in the capsule shell and therefore do not elicit any adverse reaction, in particular allergie or immunological reaction, in the patient, in which the microcapsule is preferably transplanted. Furthermore, the close contact of the erythropoietin to the liver cell stimulâtes said liver cells to perform their biological function so as to provide the patient with the biological functions of a liver.
In a particularly preferred embodiment the liver cells are contained in the microcapsule in such a concentration so as to be in physical contact to each other providing an even more pronounced effect when stimulated by the erythropoietin. Thus, the invention foresees in a particularly preferred embodiment that the liver cells contained in the microcapsules are in physical contact to each other and are in physical contact to the erythropoietin.
In the context of the présent invention the expression “liver cells are in physical contact to erythropoietin” means that erythropoietin is able to exert at least one of its biological functions on the liver cell, in particular is able to reach and being reversibly or irreversibly bound by the receptors for erythropoietin présent on the liver cell.
In the context of the présent invention the expression “liver cells being in physical contact to each other” means that the liver cells are présent in the microcapsule of the présent invention in such a close vicinity to each other that the cells touch each other and provide a stable environment closely resembling the natural physiological situation in a liver.
In the context of the présent invention the term “stimulating the liver cells” means that the erythropoietin increases the biological functionality of the liver cells, preferably in the patient in which the microcapsule is transplanted, increases the viability of the liver cells, increases their storage stability and/or increases their potential to successfully perform their biological function once being transplanted in the subject.
In the context of the présent invention “biocompatibility” means that the material, in particular the capsule shell material and/or the matrix material is able to keep the integrated liver cells viable and allow the interaction between the erythropoietin and the liver cells. In a particularly preferred embodiment the term “biocompatible” means that the material allows, preferably a long-term, implantation in a patient while still retaining the function of the embedded liver cells without eliciting any undesirable local or systemic effect in the subject, in particular allergie and immunological reactions. In a particularly preferred embodiment the term “biocompatible” means that the material is able to perform as a substrate supporting the liver cell activity including the solicitation of molecular and mechanical similar System between the liver cells and the EPO, preferably in order to optimize liver régénération without eliciting any undesirable effects in the cells and the subject.
In the context of the présent invention the term “erythropoietin” désignâtes a glycoprotein hormone that Controls erythropoieses or blood cell production, preferably a substance that, in appropriately dosage, Controls the growth, différentiation and maturation of stem cells via erythroblasts to érythrocytes.
Erythropoietin is a glycoprotein having 166 amino acids, three glycosylation sites and a molecular weight of about 34,000 Da. During EPO-induced différentiation of érythrocyte progenitor cells, globin synthesis is induced, synthesis of the heme complex is augmented and the number of ferritin receptors is increased. Thereby the cell can take up more iron and synthesize functional hemoglobin. In mature érythrocytes, hemoglobin binds oxygen. Thus the érythrocytes and the hemoglobin contained therein play a key rôle in supplying oxygen to the organism. These processes are initiated through the interaction of EPO with an appropriate receptor on the cell surface of the érythrocyte progenitor cells (Graber and Krantz, Ann. Rev. Med. 29(1978),51-56).
In the context of the présent invention the term “erythropoietin” both encompasses the wild type erythropoietin, in particular the human erythropoietin, and dérivatives therefrom. In the context of the présent invention dérivatives of erythropoietin are recombinant erythropoietin proteins which are characterized by at least one amino acid déviation, in particular délétion, addition or substitution of one more amino acid compared to the wild type EPO, and/or erythropoietin proteins with a different glycosylation pattern compared to the wild type erythropoietin. In a particularly preferred embodiment erythropoietin dérivatives are also fusion proteins or truncated proteins of wild type erythropoietin or dérivatives thereof. In a particularly pre5 ferred embodiment a dérivative of erythropoietin is also a wild type erythropoietin having a different glycosylation pattern compared to the wild type glycosylation pattern.
The term erythropoietin used here includes EPO of every origin, especially human or animal EPO. The term used here thus encom10 passes not only the naturally occurring, or in other words wild-type forms of EPO, but also its dérivatives, also termed modifications, muteins or mutants, as long as they exhibit the biological effects of wild-type erythropoietin.
In connection with the présent invention, there will be understood by 15 dérivatives also those dérivatives of erythropoietin that, while retaining the basic erythropoietin structure, are obtained by substitution of one or more atoms or molecular groups or residues, especially by substitution of sugar chains such as ethylene glycol, and/or whose amino acid sequences differ from that of the naturally occurring hu20 man or animal erythropoietin protein in at least one position but essentially hâve a high degree of homology at the amino acid level and comparable biological activity. Erythropoietin dérivatives which can be employed, for example, in the présent invention are known from WO 94/25055, EP 0148605 B1 orWO 95/05465.
Homology means especially a sequence identity of at least 80%, preferably at least 85% and particularly preferably at least more than 90%, 95%, 97% and 99%. The term homology known by the per6 son skilled in the art thus refers to the degree of relationship between two or more polypeptide molécules. This is determined by the agreement between the sequences. Such agreement can mean either identical agreement or else a conservative exchange of amino 5 acids.
According to the invention, the term dérivative also includes fusion proteins, in which functional domains of another protein are present on the N-terminal part or on the C-terminal part. In one embodiment of the invention, this other protein may be, for example, GM-CSF, 10 VEGF, PIGF, a statin or another factor that has a stimulating effect on endothélial progenitor cells. In a further embodiment of the invention, the other protein may also be a factor that has a stimulating effect on liver cells.
The différences between an erythropoietin dérivative and native or 15 wild type erythropoietin may arise, for example, through mutations such as délétions, substitutions, insertions, additions, base exchanges and/or recombinations of the nucléotide sequences coding for the erythropoietin amino acid sequences. Obviously such différences can also be naturally occurring sequence variations, such as 20 sequences from another organism or sequences that hâve mutated naturally, or mutations introduced selectively into the nucleic acid sequences coding for erythropoietin, using common means known in the art, such as Chemical agents and/or physical agents. In connection with the invention, therefore, the term dérivative also includes 25 mutated erythropoietin molécules, or in other words erythropoietin muteins.
According to the invention, peptide or protein analogs of erythropoietin may also be used. In connection with the présent invention, the term analogs includes compounds that do not hâve any amino acid sequence identical to the erythropoietin amino acid sequence but hâve a three-dimensional structure greatly resembling that of erythropoietin, so that they hâve comparable biological activity. Erythropoietin analogs may be, for example, compounds that contain, in a suitable conformation, the amino acid residues responsible for binding of erythropoietin to its receptors, and that are therefore able to simulate the essential surface properties of the erythropoietin binding région. Compounds of this type are described, for example, in Wrighton et al., Science, 273 (1996), 458.
The EPO used according to the invention can be produced in various ways, for example by isolation from human urine or from the urine or plasma (including sérum) of patients suffering from aplastic anémia (Miyaké et al., J.B.C. 252 (1977), 5558). As an example, human EPO can also be obtained from tissue cultures of human rénal cancer cells (JA Unexamined Application 55790/1979), from human lymphoblast cells, which hâve the ability to produce human EPO (JA Unexamined Application 40411/1982), and from a hybridoma culture obtained by cell fusion of a human cell line. EPO can also be produced by methods of gene technology, using suitable DNA or RNA coding for the appropriate amino acid sequence of EPO to produce the desired protein by genetic engineering, for example in a bacterium, in a yeast, or in a plant, animal or human cell line. Such methods are described, for example, in EP 0148605 B2 or EP 0205564 B2 and EP 0411678 B1.
In the context of the présent invention dérivatives of erythropoietin are in a preferred embodiment functional and clinically proven EPO dérivatives, preferably selected from the group consisting of Epoetin, also termed Procrit, Epogen, Eprex or NeoRecormon, Epoetin delta, also termed Dynepo, Darbepoetin, also called Aranesp, PDpoetin, CERA (continuous erythropoietin receptor antagonist) and methoxy polyethylene glycol-epoetin beta, also termed Mircera.
In a preferred embodiment of the présent invention a microcapsule is a, preferably spherical, bead made from a biocompatible capsule shell material which contains embedded therein the therapeutically effective amount of liver cells in physical contact to a liver cell stimulating amount of erythropoietin. In the context of the présent invention a microcapsule is preferably a sphere, preferably with a diameter from 10 pm to 10 mm, preferably 140 pm to 10 mm, preferably 50 pm to 1 mm, preferably 60 pm to 800 pm, preferably 100 to 700 pm. In a preferred embodiment of the présent invention the microcapsules of the présent invention consist of the liver cells, the erythropoietin and the biocompatible capsule shell material. Preferably in addition to the above three éléments a coating of the microcapsule and/or a biocompatible matrix in the core of the microcapsule is foreseen.
Thus, in a particularly preferred embodiment the présent invention relates to microcapsules comprising a therapeutically effective amount of liver cells encapsulated in a biocompatible matrix material in physical contact to a liver cell stimulating amount of erythropoietin.
In a particularly preferred embodiment, the liver cells are embedded in the capsule shell in form of a suspension, preferably in a cell cul ture suspension. The liver cell suspension is preferably in form of liver cells contained in a cell culture medium or in a physiologically acceptable aqueous solution. The liver cell suspension is preferably a suspension of liver cells in a cell culture medium.
In a particularly preferred embodiment, the liver cells are embedded in the matrix contained in the shell in form of a suspension, preferably in a cell culture suspension, preferably in form of liver cells contained in a cell culture medium or in a physiologically acceptable aqueous solution.
In a particularly preferred embodiment the présent invention relates to microcapsules, wherein the liver cells are selected from the group consisting of hepatic precursor cells, hepatic stem cells, hepatoblasts and hépatocytes.
In a particularly preferred embodiment the présent invention relates to microcapsules, wherein the liver cells are selected from the group consisting of hepatic precursor cells, hepatic stem cells, hepatoblasts, hépatocytes and endothélial cells.
In a furthermore preferred embodiment the présent invention relates to microcapsules, wherein the liver cells are obtained from adult liver, embryogénie liver, fêtai liver, néonatal liver or liver cell cultures. Preferably, the liver cells are living liver cells. In a preferred embodiment, the liver cells may be obtained from a living or a dead, in particular a recently deceased, donor.
In a furthermore preferred embodiment the présent invention relates to microcapsules, wherein the liver cells are human liver cells, non human primate liver cells, pig liver cells, dog liver cells, cat liver cells, rabbit liver cells, mouse liver cells or rat liver cells.
In a particularly preferred embodiment the présent invention relates to microcapsules, wherein the microcapsules hâve an average diameter from 100 to 700 pm, preferably from 200, 300, 400, 500, 600 or 650 to 700 pm.
In a particularly preferred embodiment the présent invention relates to microcapsules, wherein the therapeutically effective amount of liver cells is 104 to 108, preferably 105 to 107 liver cells/ml suspension.
In a particularly preferred embodiment the présent invention relates to microcapsules, wherein the liver cells hâve an average diameter of 8 to 14 pm, preferably 9 to 12 pm.
In a furthermore preferred embodiment the présent invention relates to microcapsules, wherein the liver cell stimulating amount of erythropoietin is 10'7 to 10-2, preferably 10'7 to 10'3, preferably 10‘7 to 10‘5 and preferably 10'6 to 10’5 U/ml suspension.
In a furthermore preferred embodiment the présent invention relates to microcapsules, wherein the EPO is wild type erythropoietin or recombinant erythropoietin.
In a furthermore preferred embodiment the présent invention relates to microcapsules, wherein the capsule shell material is selected from the group consisting of alginate, alginate-chitosan (AC), alginatepoly-L-lysine (APA), thermogelation-polymer and PEG-hydrogel.
In a furthermore preferred embodiment the présent invention relates to microcapsules, wherein the matrix material is selected from the group consisting of alginate, alginate-chitosan (AC), alginate-poly-Llysine (ARA), thermogelation-polymer and PEG-hydrogel.
In a furthermore preferred embodiment the présent invention relates to microcapsules, wherein in addition to the liver cells at least one further cell type is présent in the microcapsule.
In a particularly preferred embodiment the at least one further cell type présent in the microcapsule is selected from the group consisting of liver stellate cells, biliary cells, hemopoietic cells, monocytes, macrophage lineage cells, lymphocytes and endothélial cells.
In a furthermore preferred embodiment of the présent invention it is foreseen that the microcapsule comprises in addition to the liver cells and the EPO at least one further growth factor, preferably selected from the group consisting of HGH (human growth factor), VEGF (vascular endothélial growth factor), CSF (colony stimulating factor), thrombopoietin, SCF complex (Skpcollien, F-box containing complex), SDF (stromal cell-derived factor-1), NGF (nerve growth factor), PIGF (phosphatidyl inositol glycan anchor biosynthesis, class F), HMG coreductase inhibitor, ACE (angiotensin converting enzyme) inhibitor, AT-1 -inhibitor and an NO donor.
In a particularly preferred embodiment the présent invention relates to microcapsules, wherein the microcapsules are coated.
In a particularly preferred embodiment of the présent invention, the coating is a polymer coating, a sugar coating, a sugar alcohol coating and/or a fat or wax coating.
In a furthermore preferred embodiment the présent invention relates to a method for preparing the microcapsules according to the above comprising:
a) providing a suspension of a therapeutically effect amount of liver cells and a liver cell stimulating amount of erythropoietin,
b) mixing the suspension of the liver cells and the erythropoietin to bring them in physical contact to each other and
c) encapsulating the suspension of the liver cells and the erythropoietin in a capsule shell material so as to form the microcapsule.
In a furthermore preferred embodiment the présent invention relates to a method, wherein the microcapsules obtained in step c) are cryopreserved.
In a furthermore preferred embodiment the présent invention relates to a method for the prophylactic or therapeutic treatment of a liver disease in a subject in need thereof comprising administering the microcapsules according to the présent invention to the subject in need thereof.
In a particularly preferred embodiment the présent invention relates to a method, wherein the liver disease is hepatitis, cirrhosis, inborn errors of metabolism, acute liver failure, acute liver infections, acute Chemical toxicity, chronic liver failure, cholangiocitis, biliary cirrhosis, Alagille syndrome, alpha-1-antitrypsin deficiency, autoimmune hepatitis, biliary atresia, cancer of the liver, cystic disease of the liver, fatty liver, galactosemia, gâllstones, Gilbert’s syndrome, hemochromatosis, hepatitis A, hepatitis B, hepatitis C and other hepatitis viral infections, poryphyria, primary sclerosing cholangitis, Reye’s syndrome, sarcoidosis, tyrosinemia, type 1 glycogen storage disease or Wilson’s disease.
In a furthermore preferred embodiment the présent invention relates to a method, wherein the administration is effected by introduction of the microcapsules under the liver capsule, into the spleen, into the liver, into the liver pulp or into the spleenic artery or portai vein.
In a furthermore preferred embodiment the présent invention relates to a method for introducing liver cells into a subject comprising administering the microcapsules according to the présent invention into the subject.
In a particularly preferred embodiment of the présent invention the administration is effected by introduction into the subject in need thereof, wherein the administration is a topical, enterai or parentéral administration. In a preferred embodiment the topical administration is an epicutaneous, inhalational, vaginal or internasal administration. In a preferred embodiment the enterai administration is by mouth, by gastric feeding tube or rectally. In a preferred embodiment the parentéral administration is by injection or infusion, preferably intervenous, intraarterial, intramuscular, intracardiac, subcutaneous, intraosseous, intradermal, intrathecal, intraperitoneal or intravesical administration. In a furthermore preferred embodiment the parentéral administration is transdermal, transmucosal or inhalational.
In a furthermore preferred embodiment the présent invention relates to a method for cultivating liver cells in a culture medium, preferably in vitro, comprising culturing microcapsules according to the présent invention in a suitable culture medium and under conditions suitable for maintaining or increasing viability of the liver cells.
In a particularly preferred embodiment the présent invention relates to a method for maintaining or increasing the energy state of liver cells in a culture medium, preferably in vitro, comprising culturing microcapsules according to the présent invention in a suitable culture medium and under conditions suitable for maintaining or increasing the energy state of the liver cells.
Further preferred embodiments of the présent invention are the subject matter of subclaims.
The figure shows the ATP/ADP ratio of liver cells encapsulated with or without EPO after culture as a measure of the cell’s energy state.
Example 1
Liver cells, in the presence of EPO (5 x 10 3 units/ml), encapsulated with alginate at a concentration of 104 to 108 cells/ml into beads with an average diameter of 100 to 700 pm will fare better than liver cells encapsulated identically except without EPO. The ATP/ADP ratio is used as a measure of the cell’s energy state. If the ATP/ADP ratio is increased during the course of the experiment at a faster rate or remains higher than in the untreated cells, then this evidence would support the hypothesis.
Encapsulation of liver cells
Cell encapsulation of liver cells from a single stock of cryopreserved human liver cells was performed using an electrostatic bead génération apparatus. Liver cells were suspended in routine culture medium and mixed with 2 % sodium alginate solution in a 1:1 ratio. The resulting 1 % alginate solution containing liver cells at a concentration of 4 million cells/ml was drawn into a 1-cc syringe fitted with a 24gauge angiocatheter. The angiôcatheter was pierced at the hub with a 23-gauge needle to serve as the positive electrode in the electrostatic casting process. The syringe was loaded onto a syringe pump (Braintree Scientific BS-8000, Braintree, MA) and arranged such that the droplets ejected from the angiocatheter would fall orthogonally onto the surface of a 125 mM calcium chloride (CaCI2) solution (conβ ventional or Cytonet buffer 4 with 1 % human albumin, with 5x10' and 5 x 10’6 U/ml EPO or without EPO) in a 250 ml glass beaker. The distance from the angiocatheter tip to the surface of a CaCI2 was fixed at approximately 2.5 cm. Pump flow rates were set within the range of 0.75 to 1.5 ml/min. A grounded electrode was immersed in the CaCI2 receiving bath. An electrostatic potential was developed across the angiocatheter tip and CaCh bath using a high-voltage DC source (Spellman model RHR30PF30, Hauppauge, NY) in the range of 3.8 to 6 kV. Bead size (500 pm) was controlled by adjusting the applied potential. When the syringe pump was turned on in the presence of the high electrostatic potential, the expressed sodium alginate solution was pulled away as tiny droplets that polymerize into solid calcium alginate immediately upon contact with the CaCI2 solution.
After encapsulation the liver cell alginate beads were kept in William’s E supplemented with 10 % sérum, 244 uniVml penicillin, 0.244 mg/ml, 5.5 mM glutamine, 0.195 units/ml insulin, 0.017 ug/ml gluca gon, 0.73 ug/ml prednisolon, 0.54 ug/ml dexamethason and cultured for 2 hours.
De-encapsulation was done by placing beads in 100 mM citrate. When the alginate was dissolved, cells were washed twice with PBS 5 and pelleted by 200 x G for one minute. Métabolites were extracted by placing 4 % perchloric acid on the cells and homogenizing for 20 seconds with a hand held micro homogenizer. The sample was then centrifuged at 14,000 xG for three minutes and the supematant, with the métabolites, was removed. The perchloric acid was neutralized 10 with KOH and the insoluble potassium perchlorate was removed by centrifugation. The sample was then analyzed by an HPLC method for ATP, ADP analysis described in “Measurements of ATP in Mammalian Cells” (Manfredi et al. Methods 2002 (4), 317-326). Three parallel plates were used to perform the ATP/ADP level déterminais tion.
Results
The ATP/ADP ratio is a measure of the cell’s energy and represents the effect of ail biochemical pathways on the metabolic state of the cells. The maintenance of the ATP/ADP ratio (see figure) seen in 20 liver cells encapsulated with EPO clearly shows that the cells are able to maintain energy generating pathways which are required for every function of the cells. In this experiment, the ratio of ATP/ADP was maintained in the EPO-treatment group but not in the untreated Controls. While the EPO-treated group was able to maintain the 25 ATP/ADP ratio, the ATP/ADP ratio in Controls dropped below 0.5.
This shows that EPO may be signalling through a non-EPO receptor driven pathway to afford the cell trophic stimulation.
Patent claims
Claims (19)
- Patent claims1. Microcapsules comprising a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact to a liver cell stimulating amount of erythropoietin.5
- 2. Microcapsules according to claim 1, wherein the liver cells are selected from the group consisting of hepatic precursor cells, hepatic stem cells, hepatoblasts, endothélial cells and hépatocytes.
- 3. Microcapsules according to claim 1 or 2, wherein the liver cells are obtained from adult liver, embryogénie liver, fêtai liver, néonatal 10 liver or liver cell cultures.
- 4. Microcapsules according to any one of claims 1 to 3, wherein the liver cells are human liver cells, non-human primate liver cells, pig liver cells, dog liver cells, cat liver cells, rabbit liver cells, mouse liver cells or rat liver cells.15
- 5. The microcapsules according to any one of the preceding claims, wherein the microcapsules hâve an average diameter from 100 to 700 pm.
- 6. The microcapsules according to any one of claims 1 to 5, wherein the liver cells hâve an average diameter of 8 to 14 pm.20
- 7. The microcapsules according to any one of the preceding claims, wherein the therapeutically effective amount of liver cells is from 104 to 108 liver cells/ml suspension.
- 8. The microcapsules according to any one of the preceding daims, wherein the liver cell stimulating amount of erythropoietin is 10’7 to 10‘2, preferably 10’7 to 10'3 U/ml suspension.
- 9. The microcapsules according to any one of the preceding 5 daims, wherein erythropoietin is wild type erythropoietin or recombinant erythropoietin.
- 10. The microcapsules according to any one of the preceding daims, wherein the capsule shell is made from a biocompatible material being selected from the group consisting of alginate, alginate10 chitosan (AC), alginate-poly-L-lysine (ARA), thermogelation-polymer and PEG-hydrogel.
- 11. The microcapsules according to any one of the preceding daims, wherein in addition to the liver cells at least one further cell type is présent in the microcapsule.15
- 12. The microcapsules according to any one of the preceding daims, wherein the microcapsules are coated.
- 13. The microcapsules according to any one of the preceding daims, wherein the microcapsule contains a biocompatible matrix embedding the liver cells and the erythropoietin.20
- 14. A method for preparing the microcapsules according to any one of the preceding daims comprisinga) providing a suspension of a therapeutically effect amount of liver cells and a liver cell stimulating amount of erythropoietin,b) mixing the suspension of the liver cells and the erythropoietin to bring them in physical contact to each other andc) encapsulating the suspension of the liver cells and the erythropoietin in a biocompatible capsule shell material so as to 5 form the microcapsule.
- 15. The method according to claim 14, wherein the microcapsules obtained in step c) are cryopreserved.
- 16. Use of the microcapsules according to any one of claims 1 to 13 in the manufacture of a médicament for the prophylactic or thera10 peutic treatment of a liver disease in a subject in need thereof, wherein the microcapsules are administrable to the subject.
- 17. The use according to claim 16, wherein the liver disease is hepatitis, cirrhosis, inborn errors of metabolism, acute liver failure, acute liver infections, acute Chemical toxicity, chronic liver failure, 15 cholangiocitis, biliary cirrhosis, Alagille syndrome, alpha-1-antitrypsin deficiency, autoimmune hepatitis, biliary atresia, cancer of the liver, cystic disease of the liver, fatty liver, galactosemia, gallstones, Gilbert’s syndrome, hemochromatosis, hepatitis A, hepatitis B, hepatitis C and other hepatitis viral infections, poryphyria, primary sclerosing 20 cholangitis, Reye’s syndrome, sarcoidosis, tyrosinemia, type 1 glycogen storage disease or Wilson’s disease.
- 18. The use according to any one of claims 15 to 17, wherein the administration is effected by introduction of the microcapsules under the liver capsule, into the spleen, into the liver, into the liver pulp or 25 into the spleenic artery or portai vein.
- 19. A method for cultivating liver cells in a culture medium comprising culturing microcapsules according to any one of claims 1 to 13 in a suitable culture medium.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/430,330 | 2009-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA19940A true OA19940A (en) | 2021-08-10 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9517247B2 (en) | Encapsulated liver cell composition | |
| Edelbrock et al. | Supramolecular nanostructure activates TrkB receptor signaling of neuronal cells by mimicking brain-derived neurotrophic factor | |
| AU697600B2 (en) | Method for implanting encapsulated cells in a host | |
| Tobias et al. | Grafting of encapsulated BDNF-producing fibroblasts into the injured spinal cord without immune suppression in adult rats | |
| AU717663B2 (en) | Biocompatible immunoisolatory capsules containing genetically altered cells | |
| Shoichet et al. | Cell delivery to the central nervous system | |
| US10434068B2 (en) | Use of decellularized extracellular matrix for encapsulating cells | |
| US5908623A (en) | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules | |
| EP2322147A1 (en) | Use of microparticles containing genetically modified cells in the treatment of neurodegenerative diseases | |
| Emerich et al. | Immunoisolation cell therapy for CNS diseases | |
| OA19940A (en) | Encapsulated Liver Cell Composition | |
| Wang et al. | In vitro circadian ANP secretion by gene transferring cells encapsulated in polycaprolactone tubes: gene chronotherapy | |
| Obermeyer | Encapsulation-Free Local Delivery of BDNF Enhances Recovery in Stroke-Injured Rats | |
| JPWO2007023930A1 (en) | Brain migratory cells and their use |